Common use of Outline of study procedures Clause in Contracts

Outline of study procedures. All study procedures are outlined in the Schedule of Assessments below (Table 6.1). A more detailed description of the study procedures performed at each study stage/visit is given in the following sections. Table 6.1 Schedule of Events Hospitalization Post discharge follow-up Visits/Week Study days Screening Day (-7) to Day (-1) Day 1 Day of application(1) Daily during hospitalization(2) Day of discharge Telephone Contact Day 8 (+ 1 day) Day 30 (+ 5 days) Day 90 (+ 5 days) Day 180 (+ 7 days) End of Study Visit Follow-up Safety Visits (Months 12, 24, 36, 48 60, + 30 days) AM1 X Hospitalization X Coronary angiography, PCI, stent(1) X Informed consent X Inclusion/exclusion criteria X Pregnancy test X Demography medical history; concurrent illnesses X Physical examination X X X X X X X X Xxxxx xxxxx (temperature, arterial BP. weight) X X X X X X X X 12-lead ECG X X (4) X X X X X X Laboratory safety parameters X (5) X (6) X (6) X X X X Total CK/CK MB X X (7) NT-proBNP X X (8) X (6) X X X Echocardiography/MRI X X X X X Continuous ECG monitoring X (9) Cardiac catheterization; application of BL- 1040; coronary angiography X PTT or ACT measurements X (10) 24-hour ambulatory Xxxxxx monitoring X X X X X Safety contact for discharged patients X Minnesota Living with Heart Failure® X X X X Serious/Adverse events and concomitant medication X X X X X X X X X

Appears in 5 contracts

Samples: License and Commercialization Agreement (Bellerophon Therapeutics, Inc.), License and Commercialization Agreement (Bellerophon Therapeutics LLC), License and Commercialization Agreement (Bellerophon Therapeutics LLC)

AutoNDA by SimpleDocs

Outline of study procedures. All study procedures are outlined in the Schedule of Assessments below (Table 6.1). A more detailed description of the study procedures performed at each study stage/visit is given in the following sections. Annotated Protocol incorporating Amendment 1, Amendment 2, Amendment 3, and Amendment 4 01 December 2008 Protocol BL-1040.01, Version 5.00 Safety and Feasibility study of BL-1040 Final CONFIDENTIAL Table 6.1 Schedule of Events Visits/Week Hospitalization Post discharge follow-up Visits/Week Study days Screening Day (-7) to Day (-1) Day 1 Day of application(1) application1 Daily during hospitalization(2) hospitalization2 Day of discharge Telephone Contact Day 8 (+ ± 1 day) Day 30 (+ ± 5 days) Day 90 (+ ± 5 days) Day 180 (+ ± 7 days) End of Study Visit Follow-up Safety Visits (Months 12, 24, 36, 48 60, + ± 30 days) AM1 AMI X Hospitalization X <-----------------------X----------------------------------> Coronary angiography, PCI, stent(1) stent3 X Informed consent X Inclusion/exclusion criteria X Pregnancy test X Demography Demography; medical history; concurrent illnesses X Physical examination X X X X X X X X Xxxxx xxxxx (temperature, arterial BP. , weight) X X X X X X X X 12-lead ECG X X (4) X4 X X X X X X Laboratory safety parameters X (5) X (6) X (6) X5 X6 X6 X X X X Total CK/CK MB X X (7) X7 NT-proBNP X X (8) X (6) X6 X6 X X X Echocardiography/MRI MRI8 X X X X X Continuous ECG monitoring X (9) X9 Cardiac catheterization; application of BL- 1040BL-1040; coronary angiography X PTT or ACT measurements X (10) X10 24-hour ambulatory Xxxxxx monitoring X X X X X Safety contact for discharged patients X Minnesota Living with Heart Failure® FailureÒ X X X X Serious/Adverse events and concomitant medication X X X X X X X X X

Appears in 2 contracts

Samples: License and Commercialization Agreement (BioLineRx Ltd.), License and Commercialization Agreement (BioLineRx Ltd.)

AutoNDA by SimpleDocs
Time is Money Join Law Insider Premium to draft better contracts faster.